Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE(R)-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone and in ...

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...
The Joplin Globe

Immunomic Therapeutics Announces FDA Clearance of IND Application for a UNITE®-Based Self-Amplifying RNA Vaccine for Triple-Negative Breast Cancer, to Be Studied Alone and in ...

Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...